Our operating basic principle is to produce reliable and efficient top quality products, therefore every JSC Olainfarm product is thoroughly tested and traced in different stages of its life cycle. Our Pharmacovigilance ( surveillance on safety use of medicinal products) Group ensures the monitoring of safety use of medicinal products for which we are marketing authorization holders on the market and also for medicinal products under ongoing clinical studies.
We receive drug safety information from healthcare professionals, patients and/or their representatives, our representative offices, subsidiaries, foreign contractual partners. We carefully evaluate this information and, if necessary, report to the European Medicines Agency (EMA) EudraVigilance safety database.
The following actions in terms of safety surveillance during routine monitoring and – if necessary – emergency situations are performing by Pharmacovigilance Group regarding our medicinal products:
identification of new potential risks that may affect the safety and efficacy of the medicinal product;
analyze the received drug safety information;
evaluation the risk-benefit balance of medicinal product use
providing actual safety information regarding medicinal product useto Regulatory Authorities, health care providers, patients, contractual partners, company employees
Health care professionals, patients, their relatives, any other interested persons, if necessary, can and are welcomed to report on JSC Olainfarm medicinal products side (adverse) effects via the online forms:
During the processing of your report, you will be provided with information on the processing and storage of your personal data
You can also report to us via e-mail email@example.com or by phones: working hours: (+371) 67103724; 24/7 mobile phone (+371) 26137761, fax: (+371) 67013778 or as to the our Representative Offices / Subsidiaries at your country –
Dr. Uldis Armanis; Mg.sc.sal.EU
Qualified Person Responsible for Pharmacovigilance at JSC Olainfarm.
Data protection specialist